The Hematopoietic Innovative Therapies Division develops an international translational research, where a significant part of the funding comes from Spanish and European public and private institutions.

Our studies aim to develop new therapies for difficult-to-treat diseases. Among these diseases, a hereditary disease that causes aplastic anemia stands out, called Fanconi anemia, in which the first international clinical trial of gene therapy with a lentiviral vector developed in our laboratory is being carried out. This vector has received orphan drug designation from the European Commission. We also investigate the etiology and develop new therapies for other diseases, such as congenital anemia and immunodeficiencies, rheumatoid arthritis, or graft-versus-host disease.

In support of previous studies, the basic biology of hematopoietic and mesenchymal stem cells is also investigated. In particular, we are developing new strategies for gene therapy in different cell types, including induced pluripotent stem cells (iPSCs) which, due to their ability to generate all tissue cells, have great potential for clinical use.

Based on the ability of mesenchymal cells to facilitate tissue repair and control inflammation associated with various diseases, our laboratory is also interested in developing new cellular drugs based on the administration of these cells.

We intend to demonstrate the impact of our work through the publication of scientific articles in prestigious international journals, the development of new cellular drugs and the collaboration for the implementation of new clinical trials of gene and cellular therapy that demonstrate the efficacy and safety of advanced therapies in certain difficult-to-treat diseases.